Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

This study has been terminated.
(Enrollment terminated pending additional Phase 1 data)
Sponsor:
Collaborator:
Celgene Cellular Therapeutics
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01261403
First received: December 15, 2010
Last updated: July 16, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2013
  Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 13, 2013